Residency · Columbus, OH
Sponsored by Ohio State University Hospital
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 555 citations · Ahmad Shabsigh
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 260 citations · Ahmad Shabsigh
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 226 citations · Debasish Sundi
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
The Lancet. Oncology · 2021 · 479 citations · Eric Singer
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 84 citations · Ahmad Shabsigh
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 346 citations · Ahmad Shabsigh
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 288 citations · Eric Singer
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 247 citations · Ahmad Shabsigh